Rhythm PharmaceuticalsRYTM
RYTM
About: Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
Employees: 283
0
Funds holding %
of 7,245 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
521% more call options, than puts
Call options by funds: $21.5M | Put options by funds: $3.46M
130% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 20
23% more repeat investments, than reductions
Existing positions increased: 85 | Existing positions reduced: 69
12% more funds holding
Funds holding: 202 [Q4 2024] → 227 (+25) [Q1 2025]
3.33% less ownership
Funds ownership: 105.6% [Q4 2024] → 102.27% (-3.33%) [Q1 2025]
6% less capital invested
Capital invested by funds: $3.63B [Q4 2024] → $3.43B (-$207M) [Q1 2025]
36% less funds holding in top 10
Funds holding in top 10: 11 [Q4 2024] → 7 (-4) [Q1 2025]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$68
9%
upside
Avg. target
$79
26%
upside
High target
$92
47%
upside
7 analyst ratings
7 positive
100%
0 neutral
0%
0 negative
0%
Needham Joseph Stringer | 15%upside $72 | Buy Maintained | 7 May 2025 |
B of A Securities Tazeen Ahmad | 9%upside $68 | Buy Maintained | 10 Apr 2025 |
HC Wainwright & Co. Raghuram Selvaraju | 28%upside $80 | Buy Reiterated | 8 Apr 2025 |
Canaccord Genuity Whitney Ijem | 47%upside $92 | Buy Maintained | 8 Apr 2025 |
Wells Fargo Derek Archila | 46%upside $91 | Overweight Maintained | 7 Apr 2025 |
Financial journalist opinion
Based on 8 articles about RYTM published over the past 30 days
Neutral
GlobeNewsWire
1 week ago
Rhythm Pharmaceuticals Announces New Data Presentations on Patients with Acquired or Congenital Hypothalamic Obesity (N=35) Treated with Setmelanotide for up to Nine Months in French Early-access Program
-- New data showed setmelanotide achieved consistent, meaningful weight reduction -- -- Multiple presentations delivered at the first-ever Joint Congress between the European Society for Paediatric Endocrinology and the European Society of Endocrinology (ESPE-ESE); 32 nd annual European Congress on Obesity (ECO); and the 2025 annual meeting of the Pediatric Endocrine Society (PES 2025) -- BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the presentation of new, real-world data at two European congresses that show consistent improvements in body mass index (BMI), BMI-z, and hunger scores in a total of 35 patients with acquired or congenital hypothalamic obesity who were treated with setmelanotide for up to nine months. Physicians from Sorbonne University in Paris delivered two oral presentations with data from patients in the early-access programs in France.
Neutral
Seeking Alpha
2 weeks ago
Rhythm Pharmaceuticals, Inc. (RYTM) Q1 2025 Earnings Call Transcript
Rhythm Pharmaceuticals, Inc. (RYTM) Q1 2025 Earnings Call Transcript
Negative
Zacks Investment Research
2 weeks ago
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Lags Revenue Estimates
Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $2.35 per share a year ago.
Neutral
GlobeNewsWire
2 weeks ago
Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update
-- First quarter 2025 net product revenue from global sales of IMCIVREE ® (setmelanotide) of $37.7 million -- -- Setmelanotide pivotal Phase 3 TRANSCEND trial met primary endpoint with -19.8% placebo-adjusted BMI reduction in patients (N=120) with acquired hypothalamic obesity --
Neutral
GlobeNewsWire
2 weeks ago
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that David Meeker, M.D., Chair, President and Chief Executive Officer, will participate in fireside chats at three upcoming investor conferences: Bank of America Securities 2025 Healthcare Conference on Wednesday, May 14, 2025 at 12:20 a.m.
Negative
Zacks Investment Research
3 weeks ago
Will Rhythm Pharmaceuticals, Inc. (RYTM) Report Negative Earnings Next Week? What You Should Know
Rhythm Pharmaceuticals (RYTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Positive
Zacks Investment Research
3 weeks ago
Rhythm Pharmaceuticals (RYTM) Moves 5.2% Higher: Will This Strength Last?
Rhythm Pharmaceuticals (RYTM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Neutral
GlobeNewsWire
4 weeks ago
Rhythm Pharmaceuticals to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025
BOSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, May 7, 2025 to report its first quarter 2025 financial results and provide a corporate update.
Positive
Seeking Alpha
1 month ago
Rhythm: Late-Stage Study Win Brings About Change For Rare Obesity Disorder
Rhythm Pharmaceuticals, Inc. met primary endpoint in phase 3 TRANSCEND study, which used setmelanotide for the treatment of patients with acquired hypothalamic obesity. Regulatory submission of setmelanotide to the U.S. and EU, for the treatment of patients with acquired hypothalamic obesity, expected in Q3 of 2025. Company pushing forward with oral MC4R-specific agonist to treat patients with acquired hypothalamic obesity known as bivamelagon;
Positive
Zacks Investment Research
1 month ago
RYTM Stock Rises 17% on Meeting Goals in Hypothalamic Obesity Study
Rhythm Pharmaceuticals stock gains 17% on meeting goals with statistical significance in the late-stage acquired hypothalamic obesity study for setmelanotide.
Charts implemented using Lightweight Charts™